@article{5e308321ffe848a0a0b95aae09069ea8,
title = "Diffusion basis spectrum imaging for identifying pathologies in MS subtypes",
abstract = "Diffusion basis spectrum imaging (DBSI) combines discrete anisotropic diffusion tensors and the spectrum of isotropic diffusion tensors to model the underlying multiple sclerosis (MS) pathologies. We used clinical MS subtypes as a surrogate of underlying pathologies to assess DBSI as a biomarker of pathology in 55 individuals with MS. Restricted isotropic fraction (reflecting cellularity) and fiber fraction (representing apparent axonal density) were the most important DBSI metrics to classify MS using brain white matter lesions. These DBSI metrics outperformed lesion volume. When analyzing the normal-appearing corpus callosum, the most significant DBSI metrics were fiber fraction, radial diffusivity (reflecting myelination), and nonrestricted isotropic fraction (representing edema). This study provides preliminary evidence supporting the ability of DBSI as a potential noninvasive biomarker of MS neuropathology.",
author = "Afsaneh Shirani and Peng Sun and Kathryn Trinkaus and Perantie, {Dana C.} and Ajit George and Naismith, {Robert T.} and Schmidt, {Robert E.} and Song, {Sheng Kwei} and Cross, {Anne H.}",
note = "Funding Information: Afsaneh Shirani is funded through a clinician scientist development award from the National Multiple Sclerosis Society (USA), and a clinical research training scholarship from the American Academy of Neurology. Peng Sun: nothing to disclose. Kathryn Trinkaus: nothing to disclose. Dana Perantie: nothing to disclose. Ajit George: nothing to disclose. Robert Naismith has received honoraria for consulting for Alkermes, Biogen, Celgene, Novartis, TG Therapeutics; and for speaking for EMD Serono, Genzyme, Genentech, and Novartis. Robert Schmidt: nothing to disclose. Sheng‐Kwei Song is currently funded by NIH U01EY025500, R01NS047592, P01NS059560, and NMSS RG‐1701‐26617. Anne Cross was funded in part by the Manny & Rosalyn Rosenthal – Dr. John L Trotter MS Center Chair in Neuroimmunology of Barnes‐Jewish Hospital Foundation. She has received honoraria for consulting for Biogen, Celgene, EMD‐Serono, Genzyme, Genentech, Novartis, and TG Therapeutics. Washington University may receive royalty income based on a technology licensed by Washington University to DxGPS LLC. That technology is evaluated in this research. Funding Information: Funding information The research reported in this article was funded by a grant from the U.S. National Institutes of Health (P01 NS059560, PI: A.H.C.). The research reported in this article was funded by a grant from the U.S. National Institutes of Health (P01 NS059560, PI: A.H.C.). Publisher Copyright: {\textcopyright} 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.",
year = "2019",
month = nov,
day = "1",
doi = "10.1002/acn3.50903",
language = "English (US)",
volume = "6",
pages = "2323--2327",
journal = "Annals of Clinical and Translational Neurology",
issn = "2328-9503",
publisher = "John Wiley & Sons Inc.",
number = "11",
}